
1. Technology overview
mediVR Inc. is a company based in Toyonaka, Osaka, Japan, founded in June 2016, that develops, manufactures and sells medical devices for rehabilitation. It combines VR technology with neurotherapy based on what it calls somato-cognitive coordination therapy.
Its KAGURA system is installed at universities, rehabilitation hospitals, care homes and day-care centres across Japan. The Kagura Feedback program presents targets in VR space to prompt reaching movements and returns results through vision, hearing and touch at the same time. In October 2026 it was approved in Japan as a Class II software medical device.
2. Highlighted features & specifications
- VR reaching tasks: Targets shown in VR space prompt the user to reach with the hand.
- Multisensory feedback: Task results are returned through vision, hearing and touch simultaneously.
- Patented technology: The multisensory biofeedback function is covered by Japanese patent no. 6714285.
- Class II approval: Approved as a Class II software medical device under approval number 30800BZX00248000.
- Facility deployment: Installed in universities, rehabilitation hospitals, care homes and day-care centres.
3. Potential application
Rehabilitation hospitals in Vietnam could use VR reaching training for stroke patients with motor deficits. University hospitals could use the program in clinical research on motor relearning.
4. Benefits
Approval as a Class II software medical device gives buyers a regulated rehabilitation program. Multisensory feedback on vision, hearing and touch supports motor training. The approval covers the software alone without hardware, and the company states that cybersecurity measures meet SaMD requirements.
5. Market trends & opportunities
Software as a medical device and VR-based rehabilitation are growing in Japan as stroke and ageing populations raise rehabilitation demand. Regulated software programs make clinical adoption easier. Vietnam rehabilitation hospitals could be future buyers as digital rehab spreads in Southeast Asia.
6. Other information
Founded June 2016 in Toyonaka, Osaka, capital JPY 90 million, unlisted. The company published two English-language papers in October 2026 and does not sell directly to individuals; patients are referred to partner facilities.
One platform connecting startups, corporations, research institutions, regions and investors











Playbook & Handbook · February 6, 2026
Winning Accelerator Playbook 2026 by BambuUP
RETAIL E-COMMERCE: AI AND REAL-TIME DATA ARE TRANSFORMING HOW RETAIL BUSINESSES OPERATE








































